Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syndax Pharmaceuticals

13.00
+0.08000.62%
Post-market: 13.00-0.0100-0.08%16:22 EDT
Volume:1.34M
Turnover:17.50M
Market Cap:1.12B
PE:-3.49
High:13.59
Open:13.35
Low:12.81
Close:12.92
Loading ...
Mar 18, 2024

Major Issues Report

Form 8-K - Current report
Feb 27, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 27, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 08, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Dec 20, 2023

Major Issues Report

Form 8-K - Current report
Dec 15, 2023

Major Issues Report

Form 8-K - Current report
Dec 12, 2023

Major Issues Report

Form 8-K - Current report
Nov 29, 2023

Correspondence

Form CORRESP - Correspondence
Nov 03, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 03, 2023

Major Issues Report

Form 8-K - Current report
Nov 01, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Oct 06, 2023

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Oct 02, 2023

Major Issues Report

Form 8-K - Current report
Aug 09, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 03, 2023

Major Issues Report

Form 8-K - Current report